D853500001 (CAMBRIA 2)

Listing Category

A phase 3, open-label, randomized study to assess the efficacy and safety of Camizestrant (AZD9833), a next generation. Oral selective estrogen receptor degrader, versus standard endocrine therapy, as adjusted treatment for patients with ER+/HER2- early breast cancer and an intermediate -high or high risk of recurrence who have completed definitive locoregional treatment and have no evidence or disease

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. Robert Schumaker, Tennessee Cancer Specialists
Scroll to Top